This is a working overview of dihexa, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-10 and is reviewed periodically as new material appears.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
=== Hybridisation and polyploidy === Like common wheat, spelt is a hexaploid wheat species, which means it has six sets of chromosomes. It is derived from a hybridisation event between a domesticated tetraploid wheat such as durum wheat and another wheat species, increasing the number of sets of chromosomes. Genetic evidence indicates an initial hybridisation of a domesticated tetraploid wheat and the diploid wild goat-grass Aegilops tauschii. It further shows that spelt could have arisen as the result of a second hybridisation, this time of bread wheat and emmer, giving rise to European spelt. The spelt genome continues to influence the breeding of modern hexaploid bread wheat through recent hybridisation.
==== Lignans ==== Plant lignans are associated with high fiber foods such as cereal brans and beans are the principal precursor to mammalian lignans which have an ability to bind to human estrogen sites. Soybeans are a significant source of mammalian lignan precursor secoisolariciresinol containing 13–273 μg/100 g dry weight.
The Rush website, newly redesigned on March 12, 2007, to support the new album, also announced that the band would embark on a tour to begin in the summer. Snakes & Arrows was released on May 1, 2007, in North America, where it debuted at No. 3 on the Billboard 200 with approximately 93,000 units sold in its first week. It peaked at No. 3 in Canada and No. 13 in the UK, selling an estimated 611,000 copies worldwide. Coinciding with the beginning of Atlantic Ocean hurricane season, "Spindrift" was released as the official second radio single on June 1, 2007, while "The Larger Bowl (A Pantoum)" came out as a single on June 25, 2007. "The Larger Bowl" peaked within the top 20 of both the Billboard Mainstream Rock and Mediabase Mainstream charts, but "Spindrift" failed to appear on any commercial chart. The planned intercontinental tour in support of Snakes & Arrows began on June 13, 2007, in Atlanta, coming to a close on October 29, 2007, at Hartwall Arena in Helsinki, Finland. The 2008 portion of the Snakes & Arrows tour began on April 11, 2008, in San Juan, Puerto Rico, at José Miguel Agrelot Coliseum, and concluded on July 24, 2008, in Noblesville, Indiana at the Verizon Wireless Music Center. On April 15, 2008, the band released Snakes & Arrows Live, a double live album documenting the first leg of the tour, recorded at the Ahoy arena in Rotterdam, Netherlands on October 16 and 17, 2007. A DVD and Blu-ray recording of the same concerts was released on November 24, 2008.
=== Part IV: Transitional programme === Part IV provides a general outline of the remaining actions to be taken during the transitional period. It assigns the Council of Representatives with the responsibility to oversee the creation of a draft constitution that would eventually be presented to the Constituent Assembly before being formally adopted. Article twelve briefly mandates that elections for a National Assembly, must be held within the following two years; the Transitional Government was expected to hand over power to the parties who make up a majority of the Assembly.
Sources: en.wikipedia.org
Naturally occurring siRNAs have a well-defined structure that is a short (usually 20 to 24-bp) double-stranded RNA (dsRNA) with phosphorylated 5' ends and hydroxylated 3' ends with two overhanging nucleotides. As of 2001, it had been suggested that an enzyme referred to as Dicer catalyzed "the initiation step of RNA interference" (production of siRNAs from long dsRNAs and small hairpin RNAs). siRNAs can also be introduced into cells by transfection. Since, in principle, any gene can be knocked down by a synthetic siRNA with a complementary sequence, siRNAs are an important tool for validating gene function and drug targeting in the "post-genomic era".
== Safety == Allyl alcohol is hepatotoxic. In rats, in vivo, allyl alcohol is metabolized by liver alcohol dehydrogenase to acrolein, which can cause damage to the microtubules of rat hepatocyte mitochondria and depletion of glutathione. It is significantly more toxic than related alcohols. Its threshold limit value (TLV) is 2 ppm. It is a lachrymator.
A 2016 WHO report found that formaldehyde from second-hand vapor was around 20% greater compared to background air levels. Normal usage of e-cigarettes generates very low levels of formaldehyde. Different power settings reached significant differences in the amount of formaldehyde in the e-cigarette vapor across different devices. Later-generation e-cigarette devices can create greater amounts of carcinogens. Some later-generation e-cigarettes let users increase the volume of vapor by adjusting the battery output voltage. Depending on the heating temperature, the carcinogens in the e-cigarette vapor may surpass the levels of cigarette smoke. E-cigarettes devices using higher voltage batteries can produce carcinogens including formaldehyde at levels comparable to cigarette smoke. The later-generation and "tank-style" devices with higher voltages (5.0 V) could produce formaldehyde at comparable or greater levels than in cigarette smoke. A 2015 study hypothesized from the data that at high voltage (5.0 V), a user, "vaping at a rate of 3 mL/day, would inhale 14.4 ± 3.3 mg of formaldehyde per day in formaldehyde-releasing agents." The 2015 study used a puffing machine showed that a third-generation e-cigarette turned on to the maximum setting would create levels of formaldehyde between five and 15 times greater than with cigarette smoke.
=== From Neubauer to SRM 967 === Before Jaffe, Neubauer described a similar precipitation reaction by mixing creatinine with zinc chloride (ZnCl2) and performing a Weyl's test—the addition of SNP to NaOH and then incubating with acetic acid (CH3CO2H) to develop a color change. Until Folin developed Jaffe's reaction into a clinical procedure, Neubauer's method was how creatinine was measured. As Folin's method evolved, various techniques were implemented to remove Jaffe-reacting substances, mostly protein, from the sample and increase specificity. By the 1950s, precipitated aluminum silicate, called Lloyd's reagent, was being used to remove protein from serum, further improving accuracy. Fuller's earth was also used for protein-binding, but the reference method until the 1980s was adsorption with Lloyd's reagent. New concerns arose due to non-standardization of procedures; different labs were reading results at different endpoints. This problem was resolved with the advent of automated analyzers in the 1960s and 1970s, which introduced a kinetic reading of results rather than a specific endpoint. Kinetic Jaffe methods involve mixing serum with alkaline picrate and reading the rate of change in absorption spectrophotometrically at 520 nm. This not only standardized the procedure, but also removed the need for sample deproteinization. It also introduced two new problems—analyzers used an algorithmic compensation to correct for pseudochromogens, and calibrations were not yet standardized between instruments.
1993/1789) Criminal Justice Act 1988 (Designated Countries and Territories) (Amendment) Order 1993 (S.I. 1993/1790) Criminal Justice (International Co-operation) Act 1990 (Enforcement of Overseas Forfeiture Orders) (Amendment) Order 1993 (S.I. 1993/1791) Drug Trafficking Offences Act 1986 (Designated Countries and Territories) (Amendment) Order 1993 (S.I. 1993/1792) Haiti (United Nations Sanctions) (Channel Islands) Order 1993 (S.I. 1993/1793) Haiti (United Nations Sanctions)(Isle of Man) Order 1993 (S.I. 1993/1794) Hong Kong (British Nationality) (Amendment) Order 1993 (S.I. 1993/1795) Immigration (Guernsey) Order 1993 (S.I. 1993/1796) Immigration (Jersey) Order 1993 (S.I. 1993/1797) Iraq (United Nations) (Sequestration of Assets) (Guernsey) Order 1993 (S.I. 1993/1798) Iraq (United Nations) (Sequestration of Assets) (Jersey) Order 1993 (S.I. 1993/1799)
Sources: en.wikipedia.org
Melarsoprol is an arsenic-containing medication used for the treatment of sleeping sickness (African trypanosomiasis). It is specifically used for second-stage disease caused by Trypanosoma brucei rhodesiense when the central nervous system is involved. For Trypanosoma brucei gambiense, eflornithine or fexinidazole is usually preferred. It is effective in about 95% of people. It is given by injection and is known by patients as "fire in the veins". Melarsoprol has a high number of side effects. Common side effects include brain dysfunction, numbness, rashes, and kidney and liver problems. About 1–5% of people die during treatment, although this is tolerated due to sleeping sickness itself having a practically 100% mortality rate when untreated. In those with glucose-6-phosphate dehydrogenase (G6PD) deficiency, red blood cell breakdown may occur. It has not been studied in pregnancy. While its mechanism of action is not fully understood, its covalent binding to trypanothione to form the toxic Mel T complex is thought to play a large role. Melarsoprol has been used medically since 1949. It is on the World Health Organization's List of Essential Medicines. In regions of the world where the disease is common, melarsoprol is provided for free by the World Health Organization. It is not commercially available in Canada or the United States. In the United States, it may be obtained from the Centers for Disease Control and Prevention, while in Canada it is available from Health Canada.
==== Other countries ==== In Canada, France, the Netherlands, and Germany, mescaline in raw form and dried mescaline-containing cacti are considered illegal drugs. However, anyone may grow and use peyote (Lophophora williamsii) as well as Echinopsis pachanoi and Echinopsis peruviana (San Pedro cactus) without restriction, as they are specifically exempt from legislation. In Canada, mescaline is classified as a schedule III drug under the Controlled Drugs and Substances Act, whereas peyote is exempt. In Russia, mescaline, its derivatives, and mescaline-containing plants are banned as narcotic drugs (Schedule I).
Smell as evidence of disease has been long used, dating back to Hippocrates around 400 years BCE. It is still employed with a focus on volatile organic compounds (VOCs) found in body odor. VOCs are carbon-based molecular groups having a low molecular weight, secreted during cells' metabolic processes. Their profiles may be altered by diseases such as cancer, metabolic disorders, genetic disorders, infections, and among others. Abnormal changes in VOC composition can be identified through equipment such as gas chromatography-mass spectrometry(GC-MS), electronic nose (e-noses), and trained non-human olfaction.
=== Brand names === Janssen's patent on risperidone expired in December 2003, opening the market for cheaper generic versions from other companies, and Janssen's exclusive marketing rights expired in June 2004 (the result of a pediatric extension). It is available under many brand names worldwide. Risperidone is available as a tablet, an oral solution, and an ampule, which is a depot injection. Brand names include Risperdal, Risperdal Consta, Risperdal M-Tab, Risperdal Quicklets, Risperlet, Okedi, and Perseris.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.